Table 3.
Univariable and multivariable Cox regression model analyses of overall survival in 1424 distant metastatic bladder cancers after PSM
| Variables |
level |
Univariable | multivariable | ||||
|---|---|---|---|---|---|---|---|
| p | HR | 95% CI | p | HR | 95% CI | ||
| Age at diagnosis(years) | <70 | Ref | |||||
| >=70 | <0.0001 | 1.284 | 1.144‐1.439 | 0.044 | 1.130 | 1.003‐1.272 | |
| Race | White | Ref | |||||
| Black | 0.351 | 1.081 | 0.918‐1.272 | ||||
| Other | 0.579 | 0.927 | 0.710‐1.211 | ||||
| Sex | Female | Ref | |||||
| Male | 0.004 | 0.836 | 0.740‐0.946 | 0.442 | 0.952 | 0.840‐1.078 | |
| Primary Site | Trigone of bladder | Ref | |||||
| Dome of bladder | 0.096 | 0.661 | 0.406‐1.077 | ||||
| Lateral wall of bladder | 0.852 | 1.032 | 0.738‐1.444 | ||||
| Anterior wall of bladder | 0.253 | 0.756 | 0.468‐1.221 | ||||
| Posterior wall of bladder | 0.389 | 1.171 | 0.817‐1.678 | ||||
| Bladder neck | 0.289 | 0.806 | 0.541‐1.201 | ||||
| Ureteric orifice | 0.206 | 0.714 | 0.424‐1.204 | ||||
| Ureteric orifice | 0.014 | 0.317 | 0.127‐0.792 | ||||
| Overlapping lesion of bladder | 0.759 | 0.955 | 0.711‐1.282 | ||||
| Bladder, NOS | 0.779 | 0.961 | 0.730‐1.266 | ||||
| Histologic type | Non‐Papillary Transitional cell carcinoma | Ref | |||||
| Papillary Transitional cell carcinoma | <0.0001 | 0.768 | 0.669‐0.882 | 0.001 | 0.797 | 0.693‐0.916 | |
| Squamous cell neoplasms | 0.005 | 1.436 | 1.118‐1.844 | 0.001 | 1.575 | 1.220‐2.034 | |
| Adenomas and adenocarcinoma | 0.010 | 0.684 | 0.512‐0.913 | 0.308 | 0.860 | 0.969‐1.412 | |
| Other | 0.117 | 1.158 | 0.964‐1.391 | 0.102 | 01.170 | 0.601‐0.781 | |
| Grade | II | Ref | |||||
| III | 0.142 | 1.176 | 0.947‐1.461 | ||||
| IV | 0.654 | 1.049 | 0.851‐1.293 | ||||
| T stage | T0 | Ref | |||||
| T1 | 0.654 | 1.205 | 0.533‐2.726 | ||||
| T2 | 0.513 | 1.310 | 0.583‐2.942 | ||||
| T3 | 0.727 | 1.159 | 0.505‐2.660 | ||||
| T4 | 0.575 | 1.262 | 0.560‐2.840 | ||||
| TX +unknown | 0.490 | 1.330 | 0.592‐2.992 | ||||
| N stage | N0 | Ref | |||||
| N1 | 0.951 | 1.007 | 0.816‐1.242 | ||||
| N2 | 0.962 | 1.004 | 0.847‐1.191 | ||||
| N3 | 0.329 | 1.152 | 0.867‐1.532 | ||||
| NX +unknown | 0.962 | 1.012 | 0.881‐1.163 | ||||
| Surgery | No | Ref | |||||
| Yes | <0.0001 | 0.710 | 0.625‐0.806 | <0.0001 | 0.685 | 0.601‐0.849 | |
| Surgery about regional lymph nodes |
Surgery but no LNs removed |
Ref | |||||
| No surgery | <0.0001 | 1.348 | 1.186‐1.532 | ||||
| Surgery and LN removed | <0.0001 | 0.601 | 0.464‐0.779 | <0.0001 | 0.374 | 0.327‐0.428 | |
| Radiotherapy | Refused | Ref | |||||
| Yes | 0.356 | .0.761 | 0.426‐1.359 | ||||
| None/Unknown | 0.541 | 0.837 | 0.473‐1.480 | ||||
| Radiation sequence with surgery | No radiotherapy and/or surgery | Ref | |||||
|
Radiation after surgery |
0.082 | 0.865 | 0.735‐1.019 | ||||
|
Radiation before surgery |
0.115 | 0.524 | 0.395‐1.747 | ||||
| other | 0.624 | 0.830 | 0.395‐1.747 | ||||
| Chemotherapy | No/Unknown | Ref | |||||
| Yes | <0.0001 | 0.408 | 0.359‐0.463 | <0.0001 | 0.374 | 0.327‐0.428 | |
| Number of sites of metastases | 1 | Ref | |||||
| 2 | 0.064 | 1.137 | 0.992‐1.302 | 0.001 | 1.267 | 1.096‐1.465 | |
| 3 | <0.0001 | 1.805 | 1.444‐2.257 | <0.0001 | 1.753 | 1.359‐2.262 | |
| 4 | 0.148 | 1.523 | 0.861‐2.694 | 0.129 | 1.630 | 0.868‐3.063 | |
| Metastases sites including liver | No | Ref | |||||
| Yes | <0.0001 | 1.407 | 1.247‐1.586 | 0.001 | 1.260 | 1.098‐1.446 | |
| Metastases sites including brain | No | Ref | |||||
| Yes | 0.041 | 1.361 | 1.013‐1.827 | 0.259 | 1.210 | 0.869‐1.688 | |
The p value was bold when it <0.05.